297
Views
3
CrossRef citations to date
0
Altmetric
Review Article

Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review

ORCID Icon &
Pages 1-11 | Received 16 Jul 2018, Accepted 02 Aug 2018, Published online: 18 Nov 2018

References

  • Albers S, Meibohm B, Mir TS, Laer S. 2008. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol. 65:511–522.
  • Almazroo OA, Miah MK, Venkataramanan R. 2017. Drug metabolism in the liver. Clin Liver Dis. 21:1–20.
  • Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. 2015. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7:17–29.
  • Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. 2014. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. Drugs Context. 3:212265.
  • Bento J, Duarte R, Brito MC, Leite S, Lobato MR, Caldeira MDC, Carvalho A. 2010. Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis. BMJ Case Reports. 2010:bcr1220092554.
  • Bulitta JB, Landersdorfer CB, Huttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sorgel F. 2010. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 54:1275–1282.
  • Bulitta JB, Kinzig M, Landersdorfer CB, Holzgrabe U, Stephan U, Sorgel F. 2011. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 55:2927–2936.
  • Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 40:327–341.
  • Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. 1972. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 286:912–918.
  • Caldwell J, Gardner I, Swales N. 1995. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol. 23:102–114.
  • Carlton LD, Pollack GM, Brouwer KL. 1996. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol. J Pharm Sci. 85:473–477.
  • Chang SW, Pan WS, Lozano BD, Oleyda BL, Solano MA, Tuero I, Friedland JS, Torrico F, Gilman RH. 2013. Gut Hormones, appetite suppression and cachexia in patients with pulmonary TB. PLoS One. 8:e54564.
  • Cicoira M, Anker SD, Ronco C. 2011. Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle. 2:135–142.
  • Congleton J. 1999. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc. 58:321–328.
  • Coyne KM, Pozniak AL, Lamorde M, Boffito M. 2009. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS. 23:437–446.
  • Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. 2010. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “advanced dissolution, absorption, metabolism (ADAM)” model. CDM. 11:716–729.
  • De Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, Clark AL, Cleland JG. 2006. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 27:569–581.
  • Deans C, Wigmore SJ. 2005. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269.
  • Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al. 2008. Cachexia: a new definition. Clin Nutr. 27:793–799.
  • Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. 2011. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12:489–495.
  • Fearon KCH, Preston T. 1990. Body composition in cancer cachexia. Transfus Med Hemother.17:63–66.
  • Fricker M, Goggins BJ, Mateer S, Jones B, Kim RY, Gellatly SL, Jarnicki AG, Powell N, Oliver BG, Radford-Smith G. 2018. Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight. 3:e94040.
  • George J, Byth K, Farrell GC. 1996. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol. 11:33–39.
  • Gjerde B, Bakke PS, Ueland T, Hardie JA, Eagan TML. 2012. The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respir Med. 106:361–366.
  • Johnston C, Hilmer SN, Mclachlan A, Matthews S, Carroll PR, Kirkpatrick CM. 2014. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 70:549–555.
  • Kazeem A, Oshikoya HM, Sammons IC. 2010. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 66:1025–1035.
  • Kumar RV, Gokhale SV, Ambaye RY, Shetty PA. 1987. Pharmacokinetics of methotrexate in indian children and its relationship to nutritional status. Chemotherapy. 33:234–239.
  • Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB, Kim EH, Park SK, Yoon YR. 2009. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 13:1161–1166.
  • Leopold G, Pabst J, Ungethum W, Buhring KU. 1986. Basic pharmacokinetics of bisoprolol: a new highly Beta1-selective adrenoceptor antagonist. J Clin Pharmacol. 26:616–621.
  • Lipman J, Wallis SC, Boots RJ. 2003. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg. 97:1149–1154.
  • Loncar G, Springer J, Anker M, Doehner W, Lainscak M. 2016. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 7:246–260.
  • Mangoni A, Jansen P, Jackson S. 2009. Clinical pharmacology of ageing. In: Jackson S, Jansen P, Mangoni A, editors. Prescribing for eldely patients. Chichester: Wiley-Blackwell; pp. 1–12.
  • McGavin JK, Keating GM. 2002. Bisoprolol: a review of its use in chronic heart failure. Drugs. 62:2677–2696.
  • Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I, Kautzner J. 2013. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. 62:1660–1670.
  • Morgan DJ, Bray KM. 1994. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet. 26:292–307.
  • Muscaritoli M, Anker S, Argiles J, Aversa Z, Bauer J, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, et al. 2010. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) “ "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics&quot.” Clin Nutr. 29:154–159.
  • Nix DE, Wilton JH, Velasquez N, Budny JL, Lassman HB, Mitchell P, Divan K, Schentag JJ. 1992. Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges. J Antimicrob Chemother. 29:51–57.
  • Park SK, Yoon YR, Lee WC, Jun HM, Shon JH, Kim KA, Park JY, Shin JG. 2002. Pharmacokinetics of ofloxacin in Patients with multidrug-resistant Tuberculosis. Tuberc Respir Dis. 52:128–136.
  • Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M. 2005. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 49:3550–3553.
  • Peloquin CA, Macphee AA, Berning SE. 1993. Malabsorption of antimycobacterial medications. N Engl J Med. 329:1122–1123.
  • Pichard C, Kyle UG. 1998. Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care. 1:357–361.
  • Poggesi I, Strolin Benedetti M, Whomsley R, Lamer SL, Molimard M, Watelet JB. 2009. Pharmacokinetics in special populations. Drug Metab Rev. 41:422–454.
  • Porporato P. 2016. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5:e200.
  • Rahman A, Jafry S, Jeejeebhoy K, Nagpal AD, Pisani B, Agarwala R. 2016. Malnutrition and cachexia in heart failure. Jpen J Parenter Enteral Nutr. 40:475–486.
  • Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, et al. 2013. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis. 17:800–806.
  • Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, et al. 2007. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 50:1561–1569.
  • Sanders KJC, Kneppers AEM, Van de Bool C, Langen RCJ, Schols AMWJ. 2016. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 7:5–22.
  • Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. 2005. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 82:53–59.
  • Semple PD, Watson WS, Beastall GH, Bethel MIF, Grant JK, Hume R. 1979. Diet, absorption, and hormone studies in relation to body weight in obstructive airways disease. Thorax. 34:783–788.
  • Shammas FV, Dickstein K. 1988. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet. 15:94–113.
  • Sharkey RA, Mulloy EMT, O’Neill SJ. 1999. The acute effects of oxygen and carbon dioxide on renal vascular resistance in patients with an acute exacerbation of COPD. Chest. 115:1588–1592.
  • Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY. 2001. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 56:746–750.
  • Sica DA. 2003. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Congest Heart Fail. 9:287–292.
  • Simon ST, Niemand AM, Benalia H, Voltz R, Higginson IJ, Bausewein C. 2012. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 15:1374–1381.
  • Strenkoski LC, Nix DE. 1993. Cefpirome clinical pharmacokinetics. Clin Pharmacokinet. 25:263–273.
  • Taburet AM, Tollier C, Richard C. 1990. The effect of respiratory disorders on clinical pharmacokinetic variables. Clin Pharmacokinet. 19:462–490.
  • Tanaka E. 1998. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther. 23:403–416.
  • Te Brake LHM, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, Russel FG, Burger DM, Alisjahbana B, et al. 2015. Exposure to total and protein-unbound rifampin is not affected by malnutrition in indonesian tuberculosis patients. Antimicrob Agents Chemother. 59:3233–3239.
  • Trobec K, Kerec Kos M, Von Haehling S, Springer J, Anker SD, Lainscak M. 2013. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 8:e79603
  • Trobec KC, Grabnar I, Kerec MK, Vovk T, Trontelj J, Anker SD, Rosano G, Lainscak M. 2016. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol. 72:813–822.
  • Urso R, Blardi P, Giorgi G. 2002. A short introduction to pharmacokinetics. Eur Rev Med Pharmacol Sci. 6:33–44.
  • Von Haehling S, Anker SD. 2014. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 5:261–263.
  • Wagner PD. 2008. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 31:492–501.
  • Welage LS, Schultz RW, Schentag JJ. 1984. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 25:201–204.
  • Woosley RL. 1987. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am Heart J. 114:1280–1291.
  • Younge JO, Damen NL, Van Domburg RT, Pedersen SS. 2013. Obesity, health status, and 7-year mortality in percutaneous coronary intervention: in search of an explanation for the obesity paradox. Int J Cardiol. 167:1154–1158.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.